Biden doesn’t get it
By H. Holden Thorp,
Science
| 02. 18. 2022
It has been a rough 2 weeks for the US science community. After 4 years of bludgeoning by the Trump administration, hope resurged a year ago as a new White House promised to value science. But there have been missteps, the most recent taking place on the heels of another blunder that many saw coming. Eric Lander, who just stepped down as President Biden’s science adviser and director of the Office of Science and Technology Policy (OSTP), was a prominent research figure with a well-known record of bullying and callous actions. With the notable exception of the 500 Women Scientists organization, the scientific community was embarrassingly silent about Lander’s nomination. Not surprisingly, he is out of the White House because of the same behavioral issues. And yet, in another tone deaf move, the administration just named Francis Collins, the recently retired director of the National Institutes of Health (NIH), as Lander’s interim replacement as science adviser while asking Alondra Nelson, the OSTP’s deputy director for science and society and an experienced administrator and scholar, to temporarily direct OSTP. Apparently, Biden...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...